The Mission Report

Rodman & Renshaw

17th Annual Global Investment Conference

September 8-10, 2015 - St. Regis Hotel, New York, NY


More than 2,000 attendees will enjoy access to corporate presentations from growth companies in the healthcare,
metals and mining, technology, cleantech and other industries; investor one-on-one meetings; and daily networking opportunities over
breakfast, lunch and cocktails. For more information on Rodman & Renshaw visit

Presenting Companies: A-M N-Z


22nd Century Group, Inc. (XXII)

22nd Century Group, Inc. (NYSE MKT: XXII) is a plant biotechnology company focused on the development of technology that permits the management of nicotine levels in tobacco plants through genetic engineering and plant breeding. The company currently owns or exclusively controls more than 185 issued patents and more than 54 pending patent applications around the world. Through the development of innovative smoking cessation products and modified risk tobacco products, XXII aims to reduce the harm caused by conventional cigarettes. For more information, visit the company's website at

Abeona Therapeutics, Inc. (ABEO)

Abeona Therapeutics, Inc. (NASDAQ: ABEO) develops and delivers gene therapy and plasma-based products for severe and life-threatening diseases. The company's lead programs are ABO-101 and ABO-102, which are adeno-associated virus-based gene therapies for the treatment of Sanfilippo syndrome. Abeona expects to commence clinical trials for these programs later this year. Additionally, the company is developing ABO-201 gene therapy for the treatment of juvenile Batten disease and ABO-301 for the treatment of Fanconi anemia disorder using a novel gene editing method. For more information, visit the company's website at

Accurexa, Inc. (ACXA)

Accurexa, Inc. (OTCQB: ACXA) is focused on the development and commercialization of novel neurological therapies. The company's propriety BranchPoint device was invented to deliver therapeutics, such as stem cells or gene therapy vectors, through the radial deployment of a flexible catheter to specific brain target areas through a single penetration. In an animal study completed at the University of California, San Francisco, BranchPoint demonstrated a 75 percent improvement over the current standard of care in terms of infusion reflux. For more information, visit the company's website at

AcelRx Pharmaceuticals, Inc. (ACRX)

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. The company's leading product candidate, Zalviso™, is designed for the management of moderate-to-severe acute pain in adults in the hospital setting by utilizing a high therapeutic index opioid through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. In early September, the company plans to meet with the FDA regarding the submittal of a new drug application for Zalviso. For more information, visit the company's website at

Acme United Corporation (ACU)

Acme United Corporation (NYSE: ACU) is a worldwide supplier of innovative cutting, measuring and safety products to the school, home, office, hardware, sporting goods and industrial markets. The company sells its products under a collection of leading brands – including Westcott®, Clauss®, Camillus®, Cuda®, PhysiciansCare®, First Aid Only® and Pac-Kit®. In the coming quarters, Acme plans to bolster its sales figures through the release of new first aid, hunting and office product initiatives aimed at helping the company penetrate additional markets and bring greater value to its customers. For more information, visit the company's website at

Actinium Pharmaceuticals, Inc. (ANTM)

Actinium Pharmaceuticals, Inc. (NYSE: ANTM) is a biopharmaceutical company focused on the development of cancer drugs. The company's product candidates are based on its patented technology, which combines the cancer targeting precision of monoclonal antibodies with the power of alpha emitting radioisotopes, the most potent cancer killing agent in existence. Actinium intends to develop its drug pipeline – which includes Iomab-B for use in hematopoietic stem cell transplantation and Actimab-A for the treatment of acute myeloid leukemia – through phase II clinical trials before partnering each product candidate with an appropriate third party for completion of development and commercialization. For more information, visit the company's website at

ADMA Biologics, Inc. (ADMA)

ADMA Biologics, Inc. (NASDAQ: ADMA) is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disorder (PIDD) and certain infectious diseases. The company's product candidates target niche patient populations – including patients suffering from underlying immune deficiency diseases and patients who are immune-compromised for medical reasons. ADMA's lead product candidate, RI-002, has completed a phase III clinical trial in patients with PIDD, and the company submitted a biologics license application to the FDA on July 31, 2015. For more information, visit the company's website at

Aemetis, Inc. (AMTX)

Aemetis, Inc. (NASDAQ: AMTX) is an advanced renewable fuels and renewable chemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products. The company currently owns and operates a 60 million gallon per year ethanol production facility in the California Central Valley, as well as a 50 million gallon per year renewable chemical and advanced fuel production facility on the east coast of India. Aemetis also operates a development laboratory at the Maryland Biotech Center and holds a substantial intellectual property portfolio based on the production of renewable fuels and biochemicals. For more information, visit the company's website at

Aeterna Zentaris, Inc. (AEZS)

Aeterna Zentaris, Inc. (NASDAQ: AEZS) is a specialty biopharmaceutical company engaged in the development and commercialization of novel treatments in the fields of oncology, endocrinology and women's health. The company's product pipeline includes Macrilen™, which is currently in phase III clinical testing for the diagnosis of adult growth hormone deficiency, as well as zoptarelin doxorubicin, which is in phase III clinical development for the treatment of endometrial cancer. For more information, visit the company's website at

Aethlon Medical, Inc. (AEMD)

Aethlon Medical, Inc. (NASDAQ: AEMD) is a leading developer of affinity biofiltration devices to treat life-threatening diseases. The company's lead therapeutic candidate, Aethlon Hemopurifier®, is a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory systems of treated individuals. Hemopurifier therapy is currently being advanced under an FDA-approved clinical study. Additionally, Aethlon provides government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. For more information, visit the company's website at

Agenus Inc. (AGEN)

Agenus Inc. (NASDAQ: AGEN) is an immunology company focused on the discovery and development of novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. Using its proprietary platforms Retrocyte Display™ and SECANT®, the company is currently developing novel antibodies to target a collection of checkpoint proteins – including GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed checkpoints in partnered and internal programs. Agenus's development pipeline includes Prophage, a heat shock protein vaccine that's successfully completed phase II studies for the treatment of newly diagnosed glioblastoma multiforme. For more information, visit the company's website at

Agile Therapeutics, Inc. (AGRX)

Agile Therapeutics, Inc. (NASDAQ: AGRX) is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products that provide women with greater convenience and facilitate compliance. The company's lead product candidate, Twirla®, is a once-weekly prescription contraceptive patch currently in phase III clinical development. Twirla is based on Agile's proprietary transdermal patch technology, Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, visit the company's website at

Alliqua BioMedical, Inc. (ALQA)

Alliqua BioMedical, Inc. (NASDAQ: ALQA) is a leading provider of advanced wound care solutions. Through its sales and distribution network, the company provides a suite of technological products that enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds. Alliqua currently markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as the sorbion S® and sorbion sana® wound care products, and its TheraBond 3D® advanced dressing, which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. For more information, visit the company's website at

Amarin Corporation (AMRN)

Amarin Corporation (NASDAQ: AMRN) is a biopharmaceutical company focused on the commercialization and development of therapeutics designed to improve cardiovascular health. The company's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa®, the company's first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product currently available in the United States by prescription. For more information, visit the company's website at

American DG Energy, Inc. (ADGE)

American DG Energy, Inc. (NYSE: ADGE) is a leading supplier of low-cost energy through the commercialization of its affordable distributed power generating systems. The company's On-Site Utility™ energy solutions are available without any capital or start-up costs to the energy user, demonstrating ADGE's continuing commitment to providing institutional, commercial and small industrial facilities with clean, reliable power, cooling, heat and hot water at costs lower than those charged by local utilities. For more information, visit the company's website at

AmpliPhi Biosciences Corporation (APHB)

AmpliPhi Biosciences Corporation (OTCQB: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. The company's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is currently collaborating with a number of leading organizations – including Intrexon Corporation (XON), the U.S. Army, The Royal Brompton Clinic in London, and the University of Leicester – to rapidly advance its bacteriophage-based therapies. For more information, visit the company's website at

American Lorain Corporation (ALN)

American Lorain Corporation (NYSE: ALN) is an international processed snack foods, convenience foods and frozen foods company based in Shandong Province, China. The company recently announced the launch of a new breakfast product line, the Lorain Youtiao, to meet the increasing demand of on-the-go breakfast from Chinese consumers. American Lorain also recently launched a multi-functional breakfast food cart concept to sell Lorain branded Youtiao product alongside other Chinese breakfast food and drinks. Approximately 100 Lorain Food Carts have been introduced to 23 Chinese cities since the pilot program began in 2015. For more information, visit the company's website at

Amyris, Inc. (AMRS)

Amyris, Inc. (NASDAQ: AMRS) is an integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Through the application of its innovative bioscience solutions, the company is able to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. Amyris currently delivers its No Compromise® products in a collection of focused markets – including specialty and performance chemicals, fragrance ingredients and cosmetic emollients. For more information, visit the company's website at

Aoxing Pharmaceutical Company, Inc. (AXN)

Aoxing Pharmaceutical Company, Inc. (NYSE: AXN) is a specialty pharmaceutical company operating in China. The company specializes in the research, development, manufacture and distribution of a variety of narcotics and pain-management products. Aoxing currently operates the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Located in Shijiazhuang City, its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration. For more information, visit the company's website at

Apricus Biosciences, Inc. (APRI)

Apricus Biosciences, Inc. (NASDAQ: APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. The company has initiated a phase IIb trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions in the future. Apricus's lead commercial product, Vitaros®, is currently approved in Europe and Canada for the treatment of erectile dysfunction and is being commercialized in several European markets. For more information, visit the company's website at

ARCA biopharma, Inc. (ABIO)

ARCA biopharma, Inc. (NASDAQ: ABIO) is dedicated to the development of genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate, bucindolol, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed to treat atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to bucindolol, giving it the potential to be the first genetically-targeted preventative treatment for atrial fibrillation. The U.S. Food and Drug Administration has designated the investigation of bucindolol for the treatment of atrial fibrillation as a fast track development program. For more information, visit the company's website at

Arch Therapeutics, Inc. (ARTH)

Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company developing a novel approach to stop bleeding and control leaking during surgery and trauma care. The company's innovative self-assembling peptide technology platform has been shown to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, the AC5 Surgical Hemostatic Device, is being designed to achieve hemostasis in minimally invasive and open surgical procedures. For more information, visit the company's website at

Arno Therapeutics, Inc. (ARNI)

Arno Therapeutics, Inc. (OTCQB: ARNI) is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening diseases. The company has exclusive worldwide rights to develop and market three innovative product candidates – including Onapristone, AR-42 and AR-12. These compounds are currently in clinical or preclinical development as product candidates to treat solid tumor and hematologic malignancies, as well as infectious diseases. For more information, visit the company's website at

Ascent Solar Technologies, Inc. (ASTI)

Ascent Solar Technologies, Inc. (NASDAQ: ASTI) is a developer of thin-film photovoltaic modules with substrate materials that are more flexible, versatile and rugged than traditional solar panels. By pioneering a technology that is recognized as the future of the solar industry, the company has effectively cemented itself the manufacturing of flexible thin-film solar panels. The company's proprietary solar modules can be directly integrated into consumer products and off-grid applications, as well as aerospace and building integrated applications. Ascent's consumer products are marketed under the EnerPlex brand. For more information, visit the company's website at

Asterias Biotherapeutics, Inc. (AST)

Asterias Biotherapeutics, Inc. (NYSE: AST) is a biotechnology company in the emerging field of regenerative medicine. The company's proprietary, industry-leading platforms are based on its pluripotent stem cell and allogeneic dendritic cell technologies. Asterias is currently focused on the development of therapies based on pluripotent stem cells to treat conditions in several medical areas where there is high unmet medical need and inadequate available therapies. For more information, visit the company's website at

Atossa Genetics Inc. (ATOS)

Atossa Genetics Inc. (NASDAQ: ATOS) is focused on improving breast health through the development of innovative laboratory services, medical devices and therapeutics. The company's laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. These services, as well as Atossa's medical devices, are being developed so they can be used as companions to therapeutics aimed at the treatment of various breast health conditions. For more information, visit the company's website at

Aurinia Pharmaceuticals, Inc. (AUPH)

Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) is a late-stage biopharmaceutical company focused on the development of the therapeutic immunomodulating drug candidate voclosporin for the treatment of lupus nephritis. The company leverages its team's past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database to inform and guide its clinical development plans within this therapeutic area. For more information, visit the company's website at

Avino Silver & Gold Mines Ltd. (ASM)

Avino Silver & Gold Mines Ltd. (NYSE: ASM) is a Vancouver-based mining and exploration firm. Founded in 1968, Avino's mission is to create shareholder value through profitable organic growth at the historic Avino property near Durango, Mexico, and the Bralorne property in southwestern British Columbia, Canada. The company is committed to handling all business activities in an environmentally-responsible and cost-effective manner while contributing to the well-being of the communities in which it operates. For more information, visit the company's website at

Avita Medical Ltd. (AVMXY)

Avita Medical Ltd. (OTC: AVMXY) develops and distributes regenerative products to treat a broad range of wounds, scars and skin defects. The company's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. Its lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device; a pivotal U.S. trial is underway, with patient enrollment completion anticipated by year-end. For more information, visit the company's website at

Bellerophon Therapeutics LLC (BLPH)

Bellerophon Therapeutics LLC (NASDAQ: BLPH) is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. Its mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need. For more information, visit the company's website at

Bio Blast Pharma Ltd. (ORPN)

Bio Blast Pharma Ltd. (NASDAQ: ORPN) is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Established in 2012, the company is quickly building a diverse portfolio of product candidates with the potential to address unmet medical need for incurable rare diseases. For more information, visit the company's website at

Bio-Path Holdings, Inc. (BPTH)

Bio-Path Holdings, Inc. (NASDAQ: BPTH) is focused on developing therapeutic products that use its proprietary liposomal delivery technology, which is designed to systemically distribute nucleic acid drugs throughout the human body via a simple intravenous infusion. The company's initial focus is on cancer, and its lead product candidate, Liposomal Grb-2, will soon start a phase II study for blood cancers. The company's second drug candidate, also a liposomal antisense drug, is ready for the clinic, where it will be evaluated in lymphoma and solid tumors. For more information, visit the company's website at

Biocept, Inc. (BIOC)

Biocept, Inc. (NASDAQ: BIOC) is developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test known as a liquid biopsy. Biocept has now developed a unique, patented methodology to isolate from the blood rare cells, such as circulating tumor cells as well as cell-free circulating tumor DNA. This will allow the company to provide both FDA-approved and exploratory biomarker analysis without a tissue sample. For more information, visit the company's website at

BioLife Solutions, Inc. (BLFS)

BioLife Solutions, Inc. (NASDAQ: BLFS) is located in Bothell, Washington, on a high-tech campus that has roots as a dairy farm. The company manufactures and markets proprietary protein-free, serum-free cGMP biopreservation media for cells, tissues and organs. BioLife Solutions performs contract R&D and offers consulting to optimize customer-specific biopreservation protocols and processes. And for its direct, distributor and contract customers, it provides custom formulation, fill and finish services. For more information, visit the company's website at

Israel-based BioLineRx Ltd. (BLRX)

Israel-based BioLineRx Ltd. (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company committed to identifying, in-licensing and developing promising therapeutic candidates. The company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. For more information, visit the company's website at

BioMark Diagnostics, Inc. (BMKDF)

BioMark Diagnostics, Inc. (OTCQB: BMKDF) is an oncology- focused company on a mission to develop and market cutting-edge technologies to increase prediction and accuracy in the diagnosis of cancers. The company develops metabolomics-based diagnostic assays for the ultra-early detection of cancer before tumors become metastatic and symptomatic. BioMark presently has a promising anti-body based cancer treatment and advanced stage diagnostic technologies (originally licensed from the University of Manitoba, Canada) in the pipeline. For more information, visit the company's website at

BiondVax Pharmaceuticals Ltd. (BVXV)

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), an innovative biopharmaceutical company, is developing a universal flu vaccine designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. BiondVax's go-to-market strategy for its lead candidate, M-001, is to initially obtain regulatory approval for its use as a primer to a pandemic or seasonal vaccine; following the accumulation of enough data, BiondVax will test and gain approval for its use as a universal standalone vaccine. For more information, visit the company's website at

BioPharmX Corporation (BPMX)

Through its patented platform technologies, BioPharmX Corporation (NYSE MKT: BPMX) develops unique health and wellness products for licensing and commercialization in pharmaceutical, over-the-counter and supplemental use. The BioPharmX team aims to touch lives by providing relief and restoring well-being so the company's products address unmet needs in large, well-defined and under-served global markets including dermatology, aesthetics, and women's health. For more information, visit the company's website at

BioSpecifics Technologies Corp. (BSTC)

BioSpecifics Technologies Corp. (NASDAQ: BSTC) is a profitable, commercial-stage biopharmaceutical company that has developed injectable collagenase for 12 clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and abroad for the treatment of adult Dupuytren's contracture patients with up to two palpable cords in the same palm, and for Peyronie's disease in men with a palpable plaque and a curvature of 30 degrees or greater at the start of therapy. For more information, visit the company's website at

Biota Pharmaceuticals, Inc. (BOTA)

Biota Pharmaceuticals, Inc. (NASDAQ: BOTA) is focused on discovering and developing direct-acting antivirals to treat infections that affect a significant number of patients globally. The company has four product candidates with limited therapeutic options in development. Biota is currently enrolling patients for the phase IIb SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. For more information, visit the company's website at

BioTime, Inc. (BTX)

BioTime, Inc. (NYSE BTX) is building a dominant company in the field of regenerative medicine. The company's strategy is to be the leader in the development of pluripotent stem cell-based technologies and to apply those new technologies in the treatment of degenerative diseases that afflict large numbers of people worldwide. BioTime has also advanced other products into human clinical trials during the past year. For more information, visit the company's website at

Brainstorm Cell Therapeutics, Inc. (BCLI)

Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases, e.g. Amyotrophic Lateral Sclerosis (ALS a.k.a. Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD). NurOwn is the company's own, first-of-its-kind technology that induces autologous bone marrow-derived Mesenchymal Stem Cells (MSCs) to secrete Neurotrophic Factors (NTF). These "MSC-NTF" cells can then be transplanted back into the patient at or near the site of damage, in the spine and/or muscles, for therapeutic purposes. For more information, visit the company's website at

Cadiz Inc. (CDZI)

Founded more than 25 years ago, Cadiz Inc. (NASDAQ: CDZI) is a Los Angeles-based renewable resource company dedicated to pursuing sustainable projects through the responsible stewardship of its land and water resources. The company owns more than 70 square miles of property; its various properties, located at three sites in the eastern Mojave Desert portion of San Bernardino County, offer abundant and renewable sources of clean water, an almost pest-free environment perfect for organic farming, and excellent possibilities for solar energy production. For more information, visit the company's website at

Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma Ltd. (NYSE: CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase II and III clinical development stage, which address autoimmune-inflammatory and cancer diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. For more information, visit the company's website at

Capnia, Inc. (CAPN)

Capnia, Inc. (NASDAQ: CAPN) develops diagnostic and therapeutic products based on its proprietary technology for the precision metering of gas flow. Operating primarily in the U.S., the company offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to the degradation of red blood cells. It also develops Serenz, a therapeutic product candidate that has completed phase II clinical trials for the treatment of symptoms related to allergic rhinitis. For more information, visit the company's website at

Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is focused on discovering, developing and marketing first-in-class therapeutics for the treatment of diseases. Presently, the company is positioned at the forefront of one of the largest segments of the U.S. healthcare industry: heart disease. Capricor's lead product candidates currently target the prevention and treatment of heart failure and heart attacks, which make up a substantial portion of the estimated total annual costs of heart disease in the U.S. (over $200 billion). For more information, visit the company's website at

Capstone Therapeutics Corp. (CAPS)

Capstone Therapeutics Corp. (OTC: CAPS) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with underserved medical conditions. Its primary asset is ownership in a joint-venture development company, LipimetiX Development, Inc., based in Natick, Massachusetts. In 2012, Capstone invested $6 million in the joint venture for 60% ownership. Its partners in the venture include three PhD drug developers, The University of Alabama at Birmingham Research Foundation and scientists at The University of Alabama at Birmingham. For more information, visit the company's website at

Capstone Turbine Corporation (CPST)

Capstone Turbine Corporation (NASDAQ: CPST) is the world's leading developer and manufacturer of clean-and-green microturbine power generation systems, and was first to market with its high efficiency air bearing turbine technology. Capstone has shipped thousands of microturbines to customers worldwide. These innovative and award-winning systems have logged millions of documented runtime operating hours and are compliant with current and future emissions regulations. For more information, visit the company's website at

Cardiome Pharma Corp. (CRME)

Cardiome Pharma Corp. (NASDAQ: CRME) is an integrated, commercial, specialty pharmaceutical company dedicated to the development and commercialization of new therapies that will improve the health and quality of life of patients. The company strives to find innovative medicines that provide value to patients, physicians and healthcare systems. It has two marketed products approved in Europe and other territories: Brinavess™ (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. For more information, visit the company's website at

CASI Pharmaceuticals, Inc. (CASI)

CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs. Part of its strategy is to leverage its expertise and resources in North America and China to bring safer, more effective, and/or easier-to-use drugs to patients and to develop them more cost-effectively and faster using its unique dual development approach. For more information, visit the company's website at

Catalyst Biosciences, Inc. (CBIO)

Catalyst Biosciences, Inc. (NASDAQ: CBIO) is a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions in the fields of hemostasis. Catalyst's most advanced program, an improved next-generation coagulation Factor VIIa variant, has successfully completed a phase 1 clinical trial in severe hemophilia A and B patients. Catalyst has two other next-generation coagulation factors in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. For more information, visit the company's website at

Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. Catalyst is developing Firdapse (Amifampridine Phosphate, or 3,4-diaminopyridine phosphate) for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that Firdapse has the potential to treat other neuromuscular disorders that are resistant to currently approved therapies. For more information, visit the company's website at

Celator Pharmaceuticals, Inc. (CPXX)

Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. For more information, visit the company's website at

Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is developing agents to detect, treat and monitor a broad spectrum of cancers. With the ability to attach imaging and therapeutic agents to its proprietary delivery platform – a novel phospholipid ether (PLEs) platform technology that is a targeted delivery and retention vehicle, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer cells to "find, treat and follow" malignancies in a highly selective way. For more information, visit the company's website at

Celsion Corporation (CLSN)

Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company, is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The company's lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in phase III development for the treatment of primary liver cancer and phase II development for the treatment of recurrent chest wall breast cancer. For more information, visit the company's website at

Cerulean Pharma, Inc. (CERU)

Cerulean Pharma, Inc. (NASDAQ: CERU) is focused on making nanoparticle-drug conjugates (NDCs) designed to target rumors, reduce toxicity and enable combinations. The Cerulean team is committed to developing products to improve treatment options for people living with cancer. The company applies its Dynamic Tumor Targeting Platform to create a growing portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. For more information, visit the company's website at

Cesca Therapeutics Inc. (KOOL)

Cesca Therapeutics Inc. (NASDAQ: KOOL) is focused on three target markets: cellular therapeutics; medical/diagnostic device development and commercialization; and cell manufacturing and banking. Cesca's lead therapeutic technology platform, SurgWerks (an intraoperative rapid system for harvesting, selection/purification, testing, and delivering a therapeutic dose of autologous bone marrow derived or peripheral blood derived cells and proteins), is currently in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. For more information, visit the company's website at

Check-Cap Ltd. (CHEK)

Check-Cap Ltd. (NASDAQ: CHEK) is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose X-rays for CRC screening. The Check-Cap device requires no bowel preparation or invasive procedures, and is designed to detect clinically significant polyps with a high degree of sensitivity. Check-Cap's advanced technology has been proven in animals, and is designed to offer several advantages compared to current screening procedures. For more information, visit the company's website at

Chembio Diagnostics, Inc. (CEMI)

Chembio Diagnostics, Inc. (NASDAQ: CEMI) is committed to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). At the core of its commitment is its patented Next Generation DPP (Dual Path Platform) technology, a breakthrough in POC diagnostics, offering significant advantages over lateral-flow technologies including: significantly improved sensitivity; multiplexing – multiple test results via a single blood sample (e.g., HIV-Syphilis Assay); and application in a number of indications. For more information, visit the company's website at

ChemoCentryx, Inc. (CCXI)

ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company that specializes in creating orally administered new medicines that inhibit chemo-attractant receptors - the engines of cell migration in disease. The company focuses exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. By altering the cellular microenvironment in diseases of inflammation, autoimmunity, and cancer, the company intends to generate better treatment outcomes. For more information, visit the company's website at

China Energy Technology Corp., Ltd. (CETH)

China Energy Technology Corp., Ltd. (OTC: CETH) designs, manufactures, and sells solar water heaters and related solar products. The company offers vacuum tube solar energy collector, as well as the balcony flat panel solar energy collector type solar water heating systems that are used to generate hot water for residential use. It also provides air energy heaters and air energy floor heating systems. China Energy Technology offers its products under the Renrenjia brand. China Energy Technology Corp., Ltd. was founded in 2009 and is based in Bengbu, China. For more information, visit the company's website at

China Jo-Jo Drugstores, Inc. (CJJD)

China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD), through its own retail drugstores, wholesale distributor and online pharmacy, is a retailer and wholesale distributor of pharmaceutical and healthcare products in China. As of March 31, 2015, the company had 59 retail pharmacies in Hangzhou. China Jo-Jo's wholesale subsidiary not only supplies its retail stores, but also distributes drug and other healthcare products to other drugstores and drug vendors. For more information, visit the company's website at

China Recycling Energy Corp. (CREG)

China Recycling Energy Corp. (NASDAQ: CREG) designs, finances, constructs, operates and transfers waste energy recycling projects to mid- to large-size enterprises involved in high energy-consuming businesses. The company offers waste pressure to energy systems, including the blast furnace top gas recovery turbine unit; and waste heat-to-energy solutions such as heat power generation projects for applications in cement, steel, coking coal, and nonferrous metal industries, which collect the residual heat from various manufacturing processes. For more information, visit the company's website at

China XD Plastics Company Ltd. (CXDC)

China XD Plastics Company Ltd. (NASDAQ: CXDC) engages in researching, developing, manufacturing and selling modified plastics primarily for automotive applications in China and Dubai, the United Arab Emirates. The company's modified plastics are used to fabricate various auto components, including exteriors parts such as automobile bumpers, rearview mirrors, and license plate parts; interiors parts such as door panels, dashboards and steering wheels; and functional components including air conditioner casings, engine covers, and air ducts. For more information, visit the company's website at

Cipher Pharmaceuticals, Inc. (CPHR)

Cipher Pharmaceuticals, Inc. (NASDAQ: CPHR) is a dermatology company committed to offering healthcare professionals products that will better address their patients' needs and enrich their practices. As such, the company's innovative dermatology products provide efficacy, flexibility and convenience across a range of skin conditions. In 2015, the company has so far completed seven transactions to build out its U.S. commercial infrastructure, and to expand and strengthen its presence in Canada. By 2020, it plans to launch two new first-to-the-market products and increase its market capitalization to $1 billion. For more information, visit the company's website at

Clean Diesel Technologies, Inc. (CDTI)

Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is a cleantech emissions control company that designs, develops and manufactures sustainable solutions to reduce emissions of on- and off-road engine applications. Within its sector, the company is a global manufacturer and distributor of heavy duty diesel and light duty vehicle emissions control systems and products to major automakers and retrofitters; its business is driven by increasingly stringent global emission standards for internal combustion engines, which are major sources of a variety of harmful pollutants. For more information, visit the company's website at

Cleveland BioLabs, Inc. (CBLI)

Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company, is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy and vaccines. Its proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Operationally, the company's personnel combine proven scientific expertise and a depth of knowledge about their products' mechanisms of action into a passion for developing drugs to save lives. For more information, visit the company's website at

Codexis, Inc. (CDXS)

Codexis, Inc. (NASDAQ: CDXS) provides unique, state-of-the-art enzyme optimization services and developing biocatalyst products. The company's technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients (APIs), fine chemicals, agrochemicals, food ingredients, detergents and biofuels. They also enable rapid transfer to commercial manufacturing scale. Additionally, Codexis offers enzyme optimization and supply from small scale through to commercial quantities, and has developed and produced enzymes for more than 10 commercial processes. For more information, visit the company's website at

CoLucid Pharmaceuticals, Inc. (CLCD)

Founded in 2005, biopharmaceutical company CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) is focused on developing small molecules for the acute treatment of migraine headaches. The company's lead product candidates are oral lasmiditan, an oral tablet for the acute treatment of migraine headaches in adults; and intravenous lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. For more information, visit the company's website at

CombiMatrix Corp. (CBMX)

CombiMatrix Corp. (NASDAQ: CBMX) is a clinical diagnostic laboratory specializing in cytogenomic testing for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. As a full-scale cytogenetic and cytogenomic laboratory, CombiMatrix offers chromosomal microarray analysis, standard and customized FISH, and high resolution karyotyping to help clinicians better care for their patients. CombiMatrix's operations are made possible due, in large part, to the clinical and molecular diagnostic expertise of its medical team, and the technical expertise of our scientists and laboratory technicians. For more information, visit the company's website at

ContraVir Pharmaceuticals, Inc. (CTRV)

ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) operates as a biopharmaceutical company focused on developing targeted antiviral therapies. The company has two drug candidates in clinical studies. The first, FV-100, is now in phase III trials and being developed for the treatment of herpes zoster, or shingles and shingle pain. The second, CMX157, is a highly potent analog of the successful antiviral drug tenofovir DF (Viread). For more information, visit the company's website at

CorMedix, Inc. (CRMD)

CorMedix, Inc. (NYSE: CRMD) is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's first commercial product in Europe is Neutrolin, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in the tunneled, cuffed, central venous catheters used for vascular access in hemodialysis, oncology and critical care patients and patients receiving total parenteral nutrition, IV hydration and/or IV medications. For more information, visit the company's website at

Cortex Pharmaceuticals, Inc. (CORX)

Cortex Pharmaceuticals, Inc. (OTC: CORX) has multiple drug development programs targeted toward the treatment of brain-related breathing disorders, such as obstructive or central sleep apnea and drug-induced respiratory depression. One key program involves the development of positive allosteric modulators of the AMPA-type glutamate receptor (PAM-A compounds), which can prevent and/or rescue respiratory depression, a potentially lethal side effect of opiate analgesics or anesthetic agents such as propofol, without affecting the beneficial analgesic or anesthetic activity of such agents. For more information, visit the company's website at

Critical Outcome Technologies, Inc. (COTQF)

Critical Outcome Technologies, Inc. (OTC: COTQF) is engaged in disease-specific drug discovery, optimization and pre-clinical development using a specially developed series of computer models. COTI is focused on the discovery and pre-clinical development of small molecules for the treatment of serious diseases for which current therapy is either lacking or ineffective. The company's strategy is to partner with pharmaceutical, biotechnology and therapeutics companies at an early stage to augment their pipelines and accelerate innovation. For more information, visit the company's website at

Cyclacel Pharmaceuticals, Inc. (CYCC)

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, founded the company in 1996. In 1999, Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, also joined the company. For more information, visit the company's website at

Cymabay Therapeutics, Inc. (CBAY)

Cymabay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. The company is committed to developing breakthrough medicines that improve the lives of patients and their families. For more information, visit the company's website at

Cynapsus Therapeutics, Inc. (CYNA)

Cynapsus Therapeutics, Inc. (NASDAQ: CYNA) is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson's disease (PD). The company's lead product candidate, APL-130277, is a sublingual formulation of apomorphine hydrochloride, or apomorphine. Cynapsus has initiated its phase 3 clinical program for APL-130277, and intends to submit a new drug application in 2016. For more information, visit the company's website at

CytoDyn, Inc. (CYDY)

CytoDyn, Inc. (OTCQB: CYDY) is focused on developing new therapies that provide flexibility and freedom to people across the globe who are living with HIV. The company's lead product, PRO 140, belongs to a new class of HIV/AIDS therapeutics that protects healthy cells from viral infection. PRO 140 has several potential benefits including less frequent dosing and minimal side effects that distinguish it from currently used HIV treatments. For more information, visit the company's website at

CytoSorbents Corp. (CTSO)

CytoSorbents Corp. (NASDAQ: CTSO) is a critical care immunotherapy company using blood purification to treat life-threatening illnesses. The company has developed a new hemoperfusion technology for removing toxins from the blood associated with sepsis, kidney disease, and other conditions. With its flagship product, CytoSorb, approved in the European Union and marketed in 29 countries worldwide, CytoSorbents is committed to helping save the lives and improve the outcomes of critically-ill patients and patient undergoing cardiac surgery around the world. For more information, visit the company's website at

CytRx Corporation (CYTR)

CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical research and development company specializing in oncology. CytRx is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated, under a special protocol assessment, a pivotal phase III global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. For more information, visit the company's website at

DARA BioSciences, Inc. (DARA)

DARA BioSciences, Inc. (NASDAQ: DARA) is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments. DARA holds the exclusive U.S. marketing rights to Soltamox, a novel oral liquid formulation of tamoxifen citrate (the only FDA-approved version of it in the U.S.), which is widely used in the treatment and prevention of breast cancer. For more information, visit the company's website at

DBV Technologies S.A. (DBVT)

DBV Technologies S.A. (NASDAQ: DBVT) is committed to finding a safe, effective and patient-friendly therapy for food and pediatric allergy patients, for whom there are no currently approved treatments. The company has a proprietary platform based on its epicutaneous Viaskin patch, an electrostatic patch which offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed and developed this technology internally; however, it has scalable manufacturing capabilities. For more information, visit the company's website at

Delcath Systems, Inc. (DCTH)

Delcath Systems, Inc. (NASDAQ: DCTH) is a specialty pharmaceutical and medical device company focused on oncology and, more specifically, the treatment of primary and metastatic liver cancers. The company's proprietary product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. For more information, visit the company's website at

DelMar Pharmaceuticals, Inc. (DMPI)

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) is a clinical and commercial stage drug development company with a focus on the treatment of cancer. The company is in the midst of conducting clinical trials in the U.S. with its product candidate, VAL-083, which is designed to serve as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. For more information, visit the company's website at

DiaMedica, Inc. (DMCAF)

DiaMedica, Inc. (OTCQB: DMCAF) is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The company is preparing to advance its proprietary recombinant form of the naturally occurring uKLK1 into clinical testing for the treatment of stroke. It is also studying the potential of DM199 for the treatment of acute kidney injury and other vascular diseases. For more information, visit the company's website at

Dipexium Pharmaceuticals, Inc. (DPRX)

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late stage pharmaceutical company focused on developing and selling Locilex (pexiganan cream 0.8%), a potent and broad spectrum topical antibiotic peptide, for the treatment of mild and moderate skin and skin structure infections. The company means to establish Locilex as the standard of care for the treatment of mild infections of diabetic foot ulcers, an indication for which there are currently no products specifically approved by the U.S. Food and Drug Administration. For more information, visit the company's website at

DURECT Corporation (DRRX)

Biopharmaceutical company DURECT Corporation (NASDAQ: DRRX) has expertise in drug discovery, delivery and development, applying those skills primarily to therapeutics in the fields of pain management, CNS disorders, acute organ injury and metabolic diseases. The company's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. For more information, visit the company's website at

Echo Therapeutics, Inc. (ECTE)

Echo Therapeutics, Inc. (NASDAQ: ECTE) is changing the blood glucose monitoring industry. The company has successfully demonstrated the ability to continuously monitor blood glucose non-invasively in healthy, Type I, Type II and hospital patients. Echo's precise exfoliator is a revolution in personal monitoring technology. It is a proprietary skin preparation device that painlessly exfoliates a precise portion of the outer layer of dead skin for optimal glucose and analyte extraction. For more information, visit the company's website at


EDAP TMS S.A. (NASDAQ: EDAP) is a global leader in therapeutic ultrasound that has been present in the market for more than 35 years. The company develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. An active global operator with an extensive network of corporate offices, subsidiaries and distribution partners, EDAP TMS has developed a strong valuable patent portfolio based on its innovative technologies by constantly investing in research and development and via strategic partnerships. For more information, visit the company's website at

Elite Pharmaceuticals, Inc. (ELTP)

Elite Pharmaceuticals, Inc. (OTCQB: ELTP) is a specialty pharmaceutical company developing a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products. Elite specializes in oral sustained and controlled release drug products with high barriers to entry. The company has eight commercial products currently being sold, several additional approved products pending manufacturing site transfer, and an additional product under review pending approval by the FDA. For more information, visit the company's website at

eMagin Corporation (EMAN)

eMagin Corporation (NYSE: EMAN) is a leading manufacturer of active-matrix Organic LED (AM-OLED) microdisplays on silicon. These displays perform at low-power levels, extended temperature ranges and provide image performance not possible with LCD technologies. The company's OLED microdisplays are designed and manufactured in the U.S. Already the most power-efficient system solution for virtual imaging devices, eMagin's OLED microdisplays based on the company's new OLED-XL Technology feature significant improvements in efficiency luminance, operational lifetime and reliability. For more information, visit the company's website at

Emisphere Technologies, Inc. (EMIS)

Emisphere Technologies, Inc. (OTC BB: EMIS), a commercial stage, specialty pharmaceutical company, is currently preparing to launch its first prescription product, oral Eligen B12, in the United States. Beyond Eligen B12, the company employs its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere is also currently partnered with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, visit the company's website at

Energy Fuels, Inc. (UUUU)

Energy Fuels, Inc. (NYSE: UUUU) is America's premier integrated uranium miner. Uranium is the fuel for nuclear, which is the true "green energy" as it provides emission-free and carbon-free electricity. Energy Fuels is positioned as a major producer of uranium with existing and economic conventional and in-situ recovery (" ISR") uranium production, sales to major global nuclear utilities, excellent scalability and leverage to rising uranium prices, and the largest portfolio of NI 43-101 uranium resources in the U.S. For more information, visit the company's website at

EuroSite Power, Inc. (EUSP)

EuroSite Power, Inc. (OTC: EUSP) is a majority-owned subsidiary of American DG Energy, and has been established to expand its successful on-site utility business into the United Kingdom and Europe. The company sells the energy produced on-site by its highly efficient low carbon technologies as a risk free alternative to the outright purchase and operation of the equipment. The company also provides, finances, installs, owns, operates and maintains complete cogeneration and cooling systems tailored to a customer's specific site requirements. For more information, visit the company's website at

Eyegate Pharmaceuticals, Inc. (EYEG)

Eyegate Pharmaceuticals, Inc. (OTC: EYEG), a late-stage specialty pharmaceutical and drug delivery company, is working on developing and commercializing therapeutics and drug delivery mechanisms for treating eye diseases. The company's technology addresses two of the most prevalent issues in ophthalmic care: the existing lack of patient adherence and patient safety. This supports the company's commitment to advancing its delivery technology and therapeutic candidates with a goal of bringing new, potentially superior treatment options to patients who will most likely benefit. For more information, visit the company's website at

Fate Therapeutics, Inc. (FATE)

Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical‑stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life‑threatening diseases. The company is primarily focused on developing programmed hematopoietic cellular candidates as therapeutic entities for the treatment of hematologic malignancies, rare genetic disorders, and diseases resulting from the dysregulation of the immune system. Fate has built a novel platform to program the function and fate of cells ex vivo using pharmacologic modulators, such as small molecules. For more information, visit the company's website at

Finjan Holdings, Inc. (FNJN)

Finjan Holdings, Inc. (NASDAQ: FNJN) offers investors a diversified and unique vehicle for investing in cybersecurity-related intellectual property-backed technologies under the guidance of a proven team. Finjan's commitment to innovation in the security space continues through its investments which have culminated in the recent launch of Finjan's consulting services business, CybeRisk, development of mobile applications for the consumer and incubation of up-and-coming technology startups pioneering a new generation of security technologies. For more information, visit the company's website at

Flex Pharma, Inc. (FLKS)

The biotechnology company Flex Pharma, Inc. (NASDAQ: FLKS) is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. Flex Pharma's products will be designed to address muscle cramps and spasms by halting the repetitive firing of the motor neurons. Preliminary testing of those products in humans has shown that they can relieve electrically-induced muscle cramps in minutes, and that the effect lasts for hours. For more information, visit the company's website at

FlexShopper, Inc. (FPAY)

FlexShopper, Inc. (OTC: FPAY) provides a flexible and easy way for consumer to get furniture, electronics, appliances and other popular brand name goods through low, affordable weekly payments. The company's goal is to get customers approved for the lease amount they need so that they can take home the products they want. FlexShopper is dedicated to providing the ultimate customer service so that the customer experience is smooth from beginning to end. FlexShopper transactions are also confidential and secure. For more information, visit the company's website at

Fusion Telecommunications International, Inc. (FSNN)

Fusion Telecommunications International, Inc. (NASDAQ: FSNN), in concert with its subsidiaries, provides cloud communications, cloud connectivity, cloud computing, and managed cloud-based solutions to small, medium, and large businesses worldwide. The company also offers voice services to communications carriers. Fusion Telecommunications operates in two segments: Business Services and Carrier Services. For more information, visit the company website at

Galectin Therapeutics, Inc. (GALT)

Georgia-based Galectin Therapeutics, Inc. (NASDAQ: GALT) is a biotechnology company focused on discovery and development. The company applies its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates are based on its unique carbohydrate technology targeting galectin proteins, which are key mediators of biologic and pathologic function. Galectin is especially pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. For more information, visit the company's website at

Galena Biopharma, Inc. (GALE)

Galena Biopharma, Inc. (NASDAQ: GALE) is developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax (nelipepimut-S) currently in an international, phase III clinical trial. The company's commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. For more information, visit the company's website at

General Moly, Inc. (GMO)

U.S.-based General Moly, Inc. (NYSE: GMO) is a mineral company engaged in the exploration, development and mining of molybdenum ("moly"). The company owns two world-class moly projects located in Nevada, U.S.; an 80% interest in the fully-permitted Mt. Hope project; and 100% of the Liberty project. Headquartered in Lakewood, Colorado, General Moly's goal is to grow into the largest pure-play molybdenum producer in the world and a molybdenum supplier of choice to customers around the world. For more information, visit the company's website at

GenSpera, Inc. (GNSZ)

GenSpera, Inc. (OTC: GNSZ) is a biotechnology company focused on the development and commercialization of promising, new therapeutics. GenSpera combines powerful insights and rigorous scientific methods to create new treatment options for patients. The company's trailblazing therapeutics tackle challenging areas in oncology, and this work is motivated by a commitment to innovation, helping patients, and supported by an experienced and motivated team with deep pharmaceutical industry and scientific experience. For more information, visit the company's website at

GeoVax Labs, Inc. (GOVX)

GeoVax Labs, Inc. (OTC: GOVX) is a clinical-stage biotechnology company developing innovative human vaccines using its novel VLP (virus-like particle) platform technology. The company's proprietary vaccine technology has been developed through multi-year collaborations with the U.S. National Institutes of Health, the U.S. Centers for Disease Control and Prevention and Emory University. Ultimately, its mission is to apply its expertise in areas where there is a significant unmet medical need and commercial opportunity with the goal of improving the lives of people affected by serious and life-threatening diseases. For more information, visit the company's website at

Global Blood Therapeutics, Inc. (GBT)

Global Blood Therapeutics, Inc. (GBT) is a clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its initial product candidate, GBT440, as an oral, once-daily prophylactic therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial. In addition to GBT440 for the treatment of SCD, GBT is engaged in research and development activities targeted toward hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF), and hereditary angioedema (HAE). For more information, visit the company's website at

Great Basin Scientific, Inc. (GBSN)

Founded in 2005, Great Basin Scientific, Inc. (NASDAQ: GBSN) is a molecular diagnostics company commercializing breakthrough technologies that improve ease-of-use and deliver better cost per result for sample-to-result molecular diagnostic testing. The company's breakthrough molecular diagnostic system provides more diagnostics data per test, and its ease of use and lower price is designed to help reduce costs for the entire healthcare industry. For more information, visit the company's website at

Great Panther Silver Ltd. (GPL)

Great Panther Silver Ltd. (NYSE: GPL) is a primary silver mining and exploration company whose current activities are focused on the mining of precious metals from its two wholly owned mining operations in Mexico: the Guanajuato Mine Complex, which includes the San Ignacio satellite mine, and the Topia Mine in Durango. Recently, the company entered into a two-year option agreement to acquire a 100% interest in the Coricancha Mine Complex in the central Andes of Peru. For more information, visit the company's website at

Gulf Resources, Inc. (GURE)

Gulf Resources, Inc. (GURE) operates through two wholly-owned subsidiaries, Shouguang City Haoyuan Chemical Company Limited ("SCHC") and Shouguang Yuxin Chemical Industry Co., Limited ("SYCI"). The company believes that it is one of the largest producers of bromine in China. Elemental Bromine is used to manufacture a wide variety of compounds utilized in industry and agriculture. Through SYCI, the company manufactures chemical products utilized in a variety of applications, including oil and gas field explorations and papermaking chemical agents. For more information, visit the company's website at

Hansen Medical, Inc. (HNSN)

Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, was born from the vision of creating a new generation of advanced medical robotics – a generation that would empower and protect physicians while providing enhanced care for patients. The proprietary Sensei Robotic Catheter System and Artisan Control Catheter used in electrophysiology procedures were the first realization of this vision while the proprietary Magellan Robotic System and Magellan Robotic Catheter are the next generation of intravascular robotics technology designed for peripheral vascular interventions. For more information, visit the company's website at

Heat Biologics, Inc. (HTBX)

Heat Biologics, Inc. (NASDAQ: HTBX) is leading the immuno-oncology revolution. A clinical-stage company, Heat Biologics focuses on developing its proprietary "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic "off-the-shelf" cell-based immunotherapy to treat patients with a wide array of cancers and infectious diseases. Heat Biologics' ImPACT Immunotherapy transforms living allogeneic human cancer cells into miniature osmotic pumps that continually secrete cancer antigens to activate a patient's own immune system in order to destroy the cancer cells. For more information, visit the company's website at

Hecla Mining Company (HL)

Hecla Mining Company (NYSE: HL) is the oldest precious metals mining company in North America. The company is not only the largest and one of the lowest-cost U.S. silver producers, but also a growing gold producer with a rich history of mining that has distinguished it as a respected precious metals producer. The company owns two primary silver mines in Alaska (Greens Creek) and Idaho (Lucky Friday) and the Casa Berardi gold mine in Quebec. For more information, visit the company's website at

Hemispherx Biopharma, Inc. (HEB)

Hemispherx Biopharma, Inc. (NYSE: HEB) is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx's flagship products include Alferon N Injection and the experimental immunotherapeutics/antivirals Ampligen. Alferon N Injection is the company's injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. For more information, visit the company's website at

Highpower International, Inc. (HPJ)

Founded in 2001 and headquartered in Shenzhen, China, Highpower International, Inc. (NASDAQ: HPJ) specializes in clean energy storage. The company is focused on the development, manufacture and marketing of Ni-MH and lithium-ion rechargeable batteries, power supply systems and related products for both consumer and industrial needs. Highpower has three wholly owned subsidiaries in the Guangdong Province and two facilities in Huizhou, Guangdong and Jiangxi, Ganzhou that handle its production and research and development activities. For more information, visit the company's website at

Hydrogenics Corporation (HYGS)

Hydrogenics Corporation (NASDAQ: HYGS) has over 60 years of experience designing, manufacturing, building and installing industrial and commercial hydrogen systems around the globe. The company offers world-leading expertise for a range of applications, including: hydrogen generators for Industrial processes and fueling stations; and hydrogen fuel cells for electric vehicles, such as urban transit buses, commercial fleets, utility vehicles and electric lift trucks. For more information, visit the company's website at

I.D. Systems, Inc. (IDSY)

I.D. Systems, Inc. (NASDAQ: IDSY) has pioneered the use of RFID (radio frequency identification) technology for wireless vehicle management and fleet tracking. The initial success of I.D. Systems' emerging technology came in 1995 when the U.S. Postal Service (USPS) awarded the company a $6.6 million contract to develop and implement an innovative tracking system for monitoring the location and status of test letters and packages. For more information, visit the company's website at

IDI, Inc. (IDI)

IDI, Inc. (NYSE: IDI) is an information solutions provider focused on the data fusion market. IDI delivers otherwise unattainable insight into the ever-expanding universe of consumer- and business-centric data. Through proprietary linking technology, advanced systems architecture and a massive data repository, IDI addresses the rapidly growing need for actionable intelligence to support the risk management industry, for purposes including due diligence, risk assessment, fraud detection and prevention, authentication and verification, and more. For more information, visit the company's website at

Immune Pharmaceuticals, Inc. (IMNP)

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company's lead product candidate, bertilimumab, is entering phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid with additional studies planned for Crohn's disease and severe asthma. For more information, visit the company's website at

Immunomedics, Inc. (IMMU)

Immunomedics, Inc. (NASDAQ: IMMU) is committed to being a leading, innovative biopharmaceutical company dedicated to improving a patient's health and quality of life with novel antibody–based therapeutics for the treatment of cancer, autoimmune and other serious diseases. The company's work is driven by scientific excellence and the highest standards in a culture of integrity, pride and dedication. In doing so, Immunomedics creates value for its shareholders and a rewarding environment for its employees. For more information, visit the company's website at

Information Services Group, Inc. (III)

Information Services Group, Inc. (NASDAQ: III) is a leading technology insights, market intelligence and advisory services company, serving more than 500 clients around the world to help them achieve operational excellence. ISG supports private and public sector organizations to transform and optimize their operational environments through research, benchmarking, consulting and managed services, with a focus on information technology, business process transformation, program management services and enterprise resource planning. For more information, visit the company's website at

Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is on a quest to expand immune system stimulation to revolutionize the fight against cancers and infectious diseases. Stimulating the body's immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis, and other diseases, and the company's DNA-based immunotherapy technology platform is progressively showing its potential to establish a new paradigm to prevent and treat life-altering diseases, with validating efficacy data from a large controlled phase II study. For more information, visit the company's website at

InspireMD, Inc. (NSPR)

InspireMD, Inc. (NYSE: NSPR) was founded in 2005 with the purpose of creating a technology that could solve the problem of embolization in high risk vascular procedures. The company has grown to include a portfolio of embolic protection systems, which it both manufactures and commercializes. Today, InspireMD is a global company headquartered in Boston, Massachusetts, seeking to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection by providing a superior solution to the key clinical issues of vascular procedures. For more information, visit the company's website at

IntelGenx (IGXT)

IntelGenx (OTC: IGXT) is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company's unique multiple layer delivery system provides zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. For more information, visit the company's website at

International Stem Cell Corporation (ISCO)

International Stem Cell Corporation (OTCQB: ISCO) is a Montreal-based company devoted to developing its novel and innovative proprietary technologies for enhanced drug delivery. Through its cutting edge formulation platforms, the company has developed a broad and diverse product portfolio, including products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. For more information, visit the company's website at

Inuvo, Inc. (INUV)

Inuvo, Inc. (NYSE: INUV) is an Internet marketing and technology company that delivers purchase-ready customers to advertisers through a broad network of desktop and mobile websites and app. The company has the opportunity to work with some pretty impressive powerhouses. Inuvo thrives on the passion of its employees to be part of the big picture, voice ideas and work together as a cohesive unit, and relies on them to go out and get up-to-date information on the latest and greatest events. For more information, visit the company's website at

Inventergy Global, Inc. (INVT)

Inventergy Global, Inc. (NASDAQ: INVT) is the brainchild of one of the intellectual property world's most influential leaders, Joe Beyers. Having led global licensing for Hewlett-Packard for years, Beyers knew first-hand the challenges of leveraging IP assets for technology powerhouses. That's why he joined forces with a handpicked "A-Team" of professionals to assist corporations in getting greater value from your inventions and ideas. The Inventergy team's backgrounds span more than 100 years working for global companies, handling more than $15 billion in IP and technology transactions. For more information, visit the company's website at

InVivo Therapeutics Holdings Corp. (NVIV)

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) is on a quest to redefine the life of the spinal cord injury patient. Armed with cutting-edge technology and MIT science, experienced business and medical professionals at InVivo Therapeutics are pushing the boundaries of spinal cord injury research. As the recognized leader in the SCI field, the company has a singular focus: improving quality-of-life — and redefining life — for the SCI patients it serves. For more information, visit the company's website at

iPass, Inc. (IPAS)

iPass, Inc. (NASDAQ: IPAS) is a global Wi-Fi roaming market leader for enterprise employees and service provider subscribers. The company knits the world's commercial Wi-Fi networks together to create a single global Wi-Fi network. With the massive acceleration of the broader Wi-Fi industry, where every mobile phone, tablet and laptop is Wi-Fi enabled, and where Wi-Fi has become the preferred connectivity option for billions of devices, the company believes that it is uniquely positioned to take advantage of the expanding global demand for Wi-Fi services. For more information, visit the company's website at

Just Energy Group, Inc. (JE)

Just Energy Group, Inc. (NYSE: JE) is an energy management solutions provider specializing in electricity, natural gas, solar and green energy. With offices located across the United States, Canada, and the United Kingdom, Just Energy serves close to 2 million residential and commercial customers. The company offers a wide range of energy products and home energy management services including long-term fixed-price, variable price, and flat bill programs, smart thermostats, and residential solar panel installations. Just Energy is the parent company of Amigo Energy, Commerce Energy, Green Star Energy, Hudson Energy, JE Solar, Tara Energy and TerraPass. For more information, visit the company's website at

Kamada Ltd. (KMDA)

Kamada Ltd. (NASDAQ: KMDA) is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. For more information, visit the company's website at

La Jolla Pharmaceutical Company (LJPC)

La Jolla Pharmaceutical Company (NASDAQ: LJPC) is focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The company has several product candidates in development, including LJPC-501, the company's proprietary formulation of angiotensin II, a naturally-occurring regulator of blood pressure, and LJPC-401, its novel formulation of hepcidin, an endogenous peptide hormone that controls and regulates iron metabolism. For more information, visit the company's website at

LabStyle Innovations Corp. (DRIO)

LabStyle Innovations Corp. (OTC: DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario™ Diabetes Management Solution. Dario™ empowers people with diabetes to take charge of their health with the right tools, insights, and support in their pocket. With access to both real-time and historical blood glucose data, Dario™ is designed to spot patterns, recommend the right treatments and support behavior change efforts. For more information, visit the company's website at

Liquidmetal Technologies, Inc. (LQMT)

Liquidmetal Technologies, Inc. (OTCBB: LQMT) is a leading force in the research, development and commercialization of amorphous metals. The company's revolutionary class of patented alloys and processes form the basis of high performance materials in a broad range of medical, military, consumer, industrial and sporting goods products. Discovered by researchers at the California Institute of Technology, Liquidmetal alloys have a unique atomic structure that enables applications to achieve performance and accuracy levels that have been impossible until now. For more information, visit the company's website at

MagneGas Corporation (MNGA)

Tampa-based MagneGas Corporation (NASDAQ: MNGA) is a technology company that counts a patented process that converts liquid waste into hydrogen based fuels among its inventions. The company sells MagneGas into the metal working market as a faster, safer and hotter replacement to acetylene. In addition, the company is developing a variety of ancillary uses for MagneGas fuels by utilizing its high flame temperature for co-combustion of hydrocarbon fuels and other advanced applications. For more information, visit the company's website at

Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections. The company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, visit the company's website at

McEwen Mining, Inc. (MUX)

McEwen Mining, Inc. (NYSE: MUX) is a growing gold and silver producer in the Americas. The company's goal is to qualify for inclusion in the S&P 500. McEwen Mining's principal assets include the following: interest in Minera Santa Cruz SA, owner of the San José silver-gold mine that is located near Goldcorp's Cerro Negro project in Argentina; and phase I of the El Gallo complex in Sinaloa, Mexico. For more information, visit the company's website at

MDxHealth SA (MXDH)

MDxHealth SA (OTCBB: MXDH) is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The increased adoption of the company's ConfirmMDx for Prostate Cancer testing solution within the U.S. urology community has established MDxHealth as a market leader in the important and growing field of cancer epigenetics. The company now means to leverage its expertise in epigenetics to build on the success of ConfirmMDx for Prostate Cancer and to establish MDxHealth as the molecular diagnostics leader in urological oncology. For more information, visit the company's website at

Medovex Corporation (MDVX)

Medovex Corporation (NASDAQ: MDVX) is a company dedicated to its mission of "better living through better medicine." The highly successful and experienced healthcare executives at Medovex have a proven track record of building successful medical device and biotech companies, and Medovex will be no exception. By offering an unprecedented breadth and depth of innovative therapies that deliver value for all stakeholders – patients, providers, insurers and investors – the company intends to accomplish its mission. For more information, visit the company's website at

Merus Labs International, Inc. (MSLI)

Merus Labs International, Inc. (NASDAQ: MSLI) is on a quest to become a leading specialty pharmaceutical company with a diverse line of products in key global markets, with special geographic focus on North America and Europe. The Merus strategy is driven by an opportunistic, but highly disciplined approach to source product acquisition candidates. This approach allows Merus to source established pharmaceutical products across broad therapeutic categories. The company targets underdeveloped assets and optimizes their return through cost efficiencies, price opportunities and promotional efforts which drive volume growth. For more information, visit the company's website at

MicroVision, Inc. (MVIS)

MicroVision, Inc. (NASDAQ: MVIS) is a world leader in the innovation of a new generation of display technology. The company opens up a world of possibilities by bringing enhanced visibility to the world of mobility. All the freedom and flexibility of mobility without the limitation of the small screen – that's what original equipment manufacturers who integrate MicroVision's patented PicoP® display technology unleash for their customers. For more information, visit the company's website at


For more frequent updates, follow us on Twitter!

Home     About Us     IR Services     Investors     Partners     Market Research     Blog     Contact     Disclaimer

© 2015 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975